Home > Insider Trading > Filing (0001209191-16-152058)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479290	Revance Therapeutics Inc.	RVNC	Pharmaceutical Preparations (2834)	770551645

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1597583	Daniel L Browne	C/O Revance Therapeutics, Inc. 7555 Gateway Boulevard Newark CA 94560	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-11-25	11,178	$17.86	208,449	No	4	S	Direct
Common Stock	Disposition	2016-11-25	822	$18.70	207,627	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	409	Indirect	See footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan originally adopted by Mr. Browne on December 7, 2015.
This sale was scheduled under Mr. Browne's Rule 10b5-1 trading plan to defray Mr. Browne's tax expense relating to a Section 83(b) tax election in 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.25. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.